Florida red tide brevetoxins are sodium channel neurotoxins produced by the dinoflagellate Karenia brevis. When aerosolized, the toxin causes airway symptoms in normal individuals and patients with airway disease, but systematic exposures to define the pulmonary consequences and putative mechanisms are lacking. Here we report the effects of airway challenges with lysed cultures of Karenia brevis (crude brevetoxin), pure brevetoxin-2, brevetoxin-3, and brevetoxin-tbm (brevetoxin-2 minus the side chain) on pulmonary resistance and tracheal mucus velocity, a marker of mucociliary clearance, in allergic and nonallergic sheep. Picogram concentrations of toxin caused bronchoconstriction in both groups of sheep. Brevetoxin-tbm was the least potent, indicating the importance of the side chain for maximum effect. Both histamine H 1 -and cholinergic-mediated pathways contributed to the bronchoconstriction. A synthetic antagonist, β-naphthoyl-brevetoxin-3, and brevenal, a natural antagonist, inhibited the bronchoconstriction. Only crude brevetoxin and brevetoxin-3 decreased tracheal mucus velocity; both antagonists prevented this. More importantly, picomolar concentrations of the antagonists alone improved tracheal mucus velocity to the degree seen with mM concentrations of the sodium channel blocker amiloride. Thus, Karenia brevis, in addition to producing toxins that adversely affect the airways, may be a source of agents for treating mucociliary dysfunction.
Keywords bronchoconstriction; mucus transport; natural therapiesFlorida red tide is a harmful algal bloom caused by the dinoflagellate Karenia brevis (previously Gymnodinium breve). K. brevis produces at least nine structurally-related polyether brevetoxins (PbTxs) (1-3), with PbTx-2 and PbTx-3 being the predominant forms (4,5). As a ) is included in the provisional patent application filed on behalf of the University of North Carolina at Wilmington by aaiPharma; A.J.B. has provisional patents filed with respect to treatment of mucociliary diseases for synthetic and natural products derived from cultured red tide, and has an interest in any licensing that might arise from patents and final patents that are not filed yet and, thus, have not been thoroughly reviewed by the U.S. Patent and Copyright Office; J.R.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; A.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; T.A.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; I.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; D.G.B. has provisional patents filed with respect to treatment of mucociliary diseases for synthetic and natural products derived from cultured red tide, and has an interest in any licensing that might arise from patents and final patents not filed yet and, thus, ...